Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
JAMA. 2020.
PMID: 32392282
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1974 | 1 |
| 1975 | 2 |
| 1979 | 1 |
| 1980 | 1 |
| 1982 | 4 |
| 1983 | 3 |
| 1984 | 1 |
| 1985 | 4 |
| 1986 | 1 |
| 1987 | 2 |
| 1988 | 5 |
| 1989 | 2 |
| 1990 | 5 |
| 1991 | 7 |
| 1992 | 6 |
| 1993 | 6 |
| 1994 | 6 |
| 1995 | 15 |
| 1996 | 13 |
| 1997 | 8 |
| 1998 | 9 |
| 1999 | 8 |
| 2000 | 20 |
| 2001 | 20 |
| 2002 | 24 |
| 2003 | 22 |
| 2004 | 22 |
| 2005 | 31 |
| 2006 | 30 |
| 2007 | 28 |
| 2008 | 32 |
| 2009 | 36 |
| 2010 | 44 |
| 2011 | 56 |
| 2012 | 54 |
| 2013 | 89 |
| 2014 | 92 |
| 2015 | 101 |
| 2016 | 98 |
| 2017 | 132 |
| 2018 | 137 |
| 2019 | 138 |
| 2020 | 653 |
| 2021 | 572 |
| 2022 | 319 |
| 2023 | 229 |
| 2024 | 262 |
| 2025 | 273 |
| 2026 | 164 |
Search Results
3,382 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Int J Antimicrob Agents. 2020.
Retraction in:
Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416.
PMID: 32205204
Free PMC article.
Retracted.
Clinical Trial.
BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. ...CONCLUSION: Despite its small sample size, our survey shows that hydroxychloroqui …
BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be …
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.
Ann Rheum Dis. 2020.
PMID: 32220834
The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. ...MMF/CNI (especially tacrolimus) combination …
The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 m …
Interventions for cutaneous disease in systemic lupus erythematosus.
Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
Cochrane Database Syst Rev. 2021.
PMID: 33687069
Free PMC article.
Adverse events Data for adverse events were limited and were inconsistently reported, but hydroxychloroquine, chloroquine, and methotrexate have well-documented adverse effects including gastrointestinal symptoms, liver problems, and retinopathy for hydroxychloroquine …
Adverse events Data for adverse events were limited and were inconsistently reported, but hydroxychloroquine, chloroquine, and methot …
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
N Engl J Med. 2020.
PMID: 32379955
Free PMC article.
BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medic …
BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence su …
Chloroquine and hydroxychloroquine in covid-19.
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
BMJ. 2020.
PMID: 32269046
No abstract available.
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
JAMA. 2020.
PMID: 32392282
Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in …
DESIGN, SETTING, AND PARTICIPANTS: Retrospective multicenter cohort study of patients from a random sample of all admitted patient …
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial.
Lancet Infect Dis. 2025 Jul;25(7):788-800. doi: 10.1016/S1473-3099(24)00797-7. Epub 2025 Feb 17.
Lancet Infect Dis. 2025.
PMID: 39978372
Free article.
Clinical Trial.
BACKGROUND: Previous studies have shown that intravenous ceftriaxone or meropenem for 14 days, followed by oral trimethoprim-sulfamethoxazole for 1 year, cures 98% of people with Whipple's disease. However, intravenous therapy requires hospitalisation and carries risks for …
BACKGROUND: Previous studies have shown that intravenous ceftriaxone or meropenem for 14 days, followed by oral trimethoprim-sulfamethoxazol …
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
Pathog Glob Health. 2021 May;115(3):139-150. doi: 10.1080/20477724.2021.1884807. Epub 2021 Feb 11.
Pathog Glob Health. 2021.
PMID: 33573530
Free PMC article.
COVID-19 has quickly become a public health problem worldwide, and treatment for this new disease is needed. ...Therefore, the aim of this systematic review was to assess the association of hydroxychloroquine use with the virological cure …
COVID-19 has quickly become a public health problem worldwide, and treatment for this new disease is needed. ... …
Role of hydroxychloroquine in multidrug treatment of COVID-19.
Rev Cardiovasc Med. 2021 Sep 24;22(3):545-546. doi: 10.31083/j.rcm2203063.
Rev Cardiovasc Med. 2021.
PMID: 34565055
Free article.
No abstract available.
The understanding of the immunopathology in COVID-19 infection.
Scand J Clin Lab Invest. 2021 Jul;81(4):255-263. doi: 10.1080/00365513.2021.1892817. Epub 2021 May 25.
Scand J Clin Lab Invest. 2021.
PMID: 34032527
Review.
Coronaviruses belonging to the Coronaviridae family are single-stranded RNA viruses. The entry of SARS-CoV-2 is accomplished via ACE-2 receptors. SARS-CoV-2 infection coactivates both innate and adaptive immune responses. Although SARS …
Coronaviruses belonging to the Coronaviridae family are single-stranded RNA viruses. The entry of SARS-CoV-2 is accompl …
Cite